Quote | 89bio Inc. (NYSE:ETNB)
Last: | $ |
---|---|
Change Percent: | 2.45% |
Open: | $28.80 |
Close: | $29.30 |
High: | $31.19 |
Low: | $27.76 |
Volume: | 11,196 |
Last Trade Date Time: | 02/12/2020 04:44:06 pm |
News | 89bio Inc. (NYSE:ETNB)
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-05 08:10:19 ET More on Eli Lilly Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Eli Lilly CFO Anat Ashkenaz...
Message Board Posts | 89bio Inc. (NYSE:ETNB)
Subject | By | Source | When |
---|---|---|---|
Very, very easy to unintentionally do in the | MiamiGent | investorshub | 06/23/2023 2:51:27 PM |
MG, I'm being told that I have you | back2basics | investorshub | 06/23/2023 2:52:57 AM |
MomentumIts trading last trade up | MiamiGent | investorshub | 06/19/2023 8:25:19 PM |
bulls and bears | BigBadWolf | investorshub | 06/19/2023 12:26:25 PM |
$ETNB Time for a bounce? | subslover | investorshub | 06/19/2023 3:54:18 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...